Roch Houot

May 14, 2024 | nature.com | Roch Houot |Emmanuel Bachy |François-Xavier Gros |Catherine Thieblemont |Fabrice Jardin |Sylvain Choquet | +2 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02572-5, published online 14 September 2023In the version of the article initially published, the affiliation of Yassine Al Tabaa was incomplete and has now been updated to read “Scintidoc Nuclear Medicine Center, Clinique Clémentville, Montpellier, France” in the HTML and PDF versions of the article.

Oct 9, 2023 | nature.com | Roch Houot |Emmanuel Bachy |François-Xavier Gros |Catherine Thieblemont |Fabrice Jardin |Sylvain Choquet | +2 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02572-5, published online 14 September 2023.

Sep 14, 2023 | nature.com | Roch Houot |Emmanuel Bachy |Catherine Thieblemont |Fabrice Jardin |Sylvain Choquet |Karin Tarte | +2 more

AbstractAxicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma (LBCL) considered eligible for autologous stem cell transplantation (ASCT); however, in clinical practice, roughly half of patients with R/R LBCL are deemed unsuitable candidates for ASCT. The efficacy of axi-cel remains to be ascertained in transplant-ineligible patients.